1157. Clinical Safety, Efficacy, and Pharmacokinetics of Fosmanogepix, a Novel First-in-class Antifungal, in Patients with Renal Insufficiency: Subset Analysis from a Phase 2 Candidemia Trial

BACKGROUND: Fosmanogepix (FMGX) is a first-in-class antifungal agent, with a unique MOA targeting the fungal enzyme Gwt1, and broad-spectrum activity against yeasts and molds, including fungi resistant to other antifungal agents. Patients with candidemia often have underlying renal insufficiency or...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Open Forum Infect Dis
Autori principali: Bulpa, Pierre, Rahav, Galia, Oren, Ilana, Aoun, Mickaël, Thompson, George R, Pappas, Peter, Kullberg, Bart Jan, Vazquez, Jose A, Barbat, Sara, Wedel, Pamela, Schlamm, Haran T, Hodges, Michael
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2020
Soggetti:
Poster Abstracts
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7776851/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.1343
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi